))
Exchanges at Goldman Sachs: A Revolution in Cancer Treatment
Archived series ("HTTP Redirect" status)
Replaced by: owltail.com
When?
This feed was archived on March 15, 2018 18:47 (
Why? HTTP Redirect status. The feed permanently redirected to another series.
What now? If you were subscribed to this series when it was replaced, you will now be subscribed to the replacement series. This series will no longer be checked for updates. If you believe this to be in error, please check if the publisher's feed link below is valid and contact support to request the feed be restored or if you have any other concerns about this.
Manage episode 195891340 series 1941488
Content provided by Best Podcasts like We Study Billionaires/The Investors Podcast - 3 Episodes per week. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Best Podcasts like We Study Billionaires/The Investors Podcast - 3 Episodes per week or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Published on 05 Dec 2014. Jami Rubin, head of US healthcare research at Goldman Sachs, discusses how immuno-oncology is transforming the treatment of cancer. This podcast was recorded on November 25, 2014 This podcast should not be copied, distributed, published or reproduced, in whole or in part. The information contained in this podcast does not constitute research or a recommendation from any Goldman Sachs entity to the listener. Neither Goldman Sachs nor any of its affiliates makes any representation or warranty, as to the accuracy or completeness of the statements or any information contained in this podcast and any liability therefor (including in respect of direct, indirect or consequential loss or damage) is expressly disclaimed. The views expressed in this podcast are not necessarily those of Goldman Sachs, and Goldman Sachs is not providing any financial, economic, legal, accounting or tax advice or recommendations in this podcast. In addition, the receipt of this podcast by any listener is not to be taken as constituting the giving of investment advice by Goldman Sachs to that listener, nor to constitute such person a client of any Goldman Sachs entity.
…
continue reading
65 episodes
Share
